ArticleFrontiers in immunology2021
What Basophil Testing Tells Us About CSU Patients - Results of the CORSA Study.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 40 citations in OpenAlex.
- Development and validation of a clinically applicable biomarker panel for identifying autoimmune type IIb chronic spontaneous urticaria.The World Allergy Organization journal · 2026Article
- Chronic Spontaneous Urticaria in the Era of Targeted Therapy: From Pathogenic Mechanisms to Precision Medicine.Pharmaceutics · 2026Review
- Research on chronic urticaria and angioedema: A bibliometric analysis of Web of Science Core Collection.Immunologic research · 2026Review
- Treatment Approaches for Omalizumab-Refractory Chronic Spontaneous Urticaria.Journal of inflammation research · 2026Review
- Diagnostic testing for chronic spontaneous urticaria with or without angioedema: The do's, don't and maybe's.The World Allergy Organization journal · 2025Review
- Integrated Diagnostic Approach Using Basophil Activation Test and IgE Assays for Shrimp and Prawn Allergy.Medicina (Kaunas, Lithuania) · 2025Article
- Clinical and molecular aspects of managing chronic spontaneous urticaria: identifying endotypes, phenotypes, and determinants of treatment response and resistance.Frontiers in allergy · 2025Review
- Factors associated with quality of life of chronic spontaneous urticaria patients in a Vietnamese population.PloS one · 2025Article
- Autoimmune Mast Cell Activation Test as a Diagnostic Tool in Chronic Spontaneous Urticaria.International journal of molecular sciences · 2024Article
- Immunopathogenesis of urticaria: a clinical perspective on histamine and cytokine involvement.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Review
- Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.Frontiers in immunology · 2024Article
- Biomarkers of Autoimmune Chronic Spontaneous Urticaria.Current allergy and asthma reports · 2023Review
- Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria.International journal of molecular sciences · 2023Review
- Urticaria.Nature reviews. Disease primers · 2022Review
- Detection of serum IgG autoantibodies to FcεRIα by ELISA in patients with chronic spontaneous urticaria.PloS one · 2022Article
- Resistant Chronic Spontaneous Urticaria - A Case Series Narrative Review of Treatment Options.Allergy & rhinology (Providence, R.I.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Basophil testing is the most effective single approach for diagnosing type-IIb autoimmune chronic spontaneous urticaria (TIIbaiCSU). A positive basophil test has been linked to long disease duration, higher disease activity, a poor response to antihistamines and omalizumab, and a better response to cyclosporine and fenebrutinib. As of now it is unclear what other features are connected to a positive basophil test in chronic spontaneous urticaria (CSU). We aimed to identify features of basophil test-positive CSU patients. We performed a cross-sectional study of 85 CSU patients. Basophil testing was done with the basophil activation test (BAT) and the basophil histamine release assay (BHRA). Data were analysed using SPSS: Student's t-test, Chi-square test, Odds Ratio, Spearman's correlation test. Of 85 CSU patients, 44% and 28% tested positive with the BAT and BHRA, respectively. These patients showed higher disease activity and impact, lower levels of disease control and total serum IgE, as well as higher rates of having a positive autologous serum skin test (ASST), angioedema, nocturnal symptoms, symptoms for >5 days/week, and thyroid autoantibodies. The ASST, by itself, was not a good predictor of basophil test results, but it predicted a positive basophil test in up to 100% of cases when combined with angioedema, thyroid autoantibodies or low IgE. In conclusion, a positive basophil test is linked to known features of TIIbaiCSU and novel characteristics including nocturnal symptoms. Further studies on basophil test-positive and -negative CSU patients can help to better understand CSU endotypes and to develop better management approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.